Which microorganisms are associated with lichen planus and what screening tests should be performed for them?

Lichen Planus Association with Microorganisms

Hepatitis C virus (HCV) is the primary microorganism associated with lichen planus, particularly oral lichen planus, and HCV screening should be performed in all patients with this diagnosis. 1, 2

Primary Microorganism Association

Hepatitis C Virus (HCV)

The association between HCV and lichen planus, especially oral lichen planus (LP), has been widely documented 1, 2. This relationship appears to result from a T-cell mediated autoimmune reaction triggered by the virus 2. The strength of this association varies by geographic region and may be influenced by genetic factors including HLA-DR associations 2.

Critical caveat: The geographic variability of this association is substantial—some regions show much stronger HCV-LP correlations than others, so local epidemiology should inform your clinical suspicion 2.

Screening Recommendations

Mandatory Screening

• HCV antibody testing with confirmatory HCV RNA if positive 1
• This should be performed in all patients diagnosed with oral lichen planus 1, 2

Additional Microorganisms to Consider

Recent research has identified several other microorganisms associated with OLP, though these represent colonization patterns rather than established causative relationships:

Bacterial organisms found in higher prevalence in OLP patients 3:

• Helicobacter pylori (45.21% of OLP cases vs 13.46% controls)
• Candida albicans (47.12% of OLP cases vs 9.43% controls)
• Periodontopathogenic bacteria (33.14% vs 13.46%)
• Mycoplasma salivarium (46.47% vs 6.45%)

Viral organisms 3:

• HPV-16 (38.12% of OLP cases vs 11.24% controls)
• HPV-18 (32.43% vs 11.43%)

Oral microbiome alterations 4, 5, 6:

• Increased Prevotella and Solobacterium
• Increased Candida and Aspergillus species
• Decreased Actinobacteria and Proteobacteria
• Increased Porphyromonas (correlates with IL-17 levels)

Clinical Algorithm for Screening

1. All OLP patients:

   • HCV antibody testing (mandatory)
   • If positive: HCV RNA confirmation and genotyping

2. Consider additional testing based on clinical presentation:

   • Oral candidiasis symptoms → Candida culture
   • Gastrointestinal symptoms → H. pylori testing
   • Persistent/refractory disease → Consider HPV testing (though clinical utility remains unclear)

3. Do NOT routinely screen for:

   • Oral microbiome composition (research tool only, not clinically actionable)
   • Mycoplasma salivarium (no established treatment benefit)
   • Periodontopathogenic bacteria beyond standard periodontal assessment

Treatment Implications

Important warning: If HCV is detected, avoid interferon-based antiviral therapy, as type-1 interferons are major drivers of lichenoid inflammation and can worsen established LP or induce new lichenoid lesions 2. Direct-acting antivirals (DAAs) are preferred, though data on their impact on LP remain limited 2.

For patients requiring systemic treatment of LP with concurrent HCV, careful monitoring of liver function tests is essential, and drug-drug interactions between DAAs and immunosuppressants (particularly cyclosporine) must be evaluated 2.

Quality of Life Consideration

The microbiome alterations, particularly Candida overgrowth, become clinically significant during corticosteroid therapy for OLP. Commensal taxa like Streptococcus, Rothia, and Actinomyces appear protective against candidiasis, while anaerobes including Porphyromonas gingivalis and Prevotella multiformis correlate with fungal proliferation 7. This supports prophylactic antifungal consideration in high-risk patients receiving topical corticosteroids.